Related Experiment Video
Updated: Oct 3, 2025

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
A Comprehensive Approach to Managing Methamphetamine-Associated Cardiomyopathy
Michael Osekowski1, Adam Trytell1, Andre La Gerche1,2,3
1St Vincent's Hospital Melbourne, Fitzroy, VIC, 3065, Australia.
Abstract:
Methamphetamines are illicit drugs of the amphetamine-type stimulant class that have been increasing in popularity, availability, and purity in recent decades. As a result, rates of methamphetamine-associated cardiomyopathy (MAC) are rising globally. MAC is associated with high rates of sudden cardiac arrest, late presentation, and poor outcomes. This review discusses the medical management of MAC, including anticipated challenges specific to methamphetamine users. Not only are patients with MAC more likely to present at a younger age and with multisystem disease than patients with cardiomyopathy of other etiologies, but there may also be significant behavioral, psychosocial, financial, and system-based challenges to providing the best medical care. An individualized treatment plan that emphasizes methamphetamine abstinence as the foundation of therapy, as well as introducing optimal heart failure therapy and providing multidisciplinary support is likely to result in optimal outcomes. Given the potential reversibility of MAC, institution of guideline-directed heart failure therapy and patient support for adherence to therapy and abstinence from methamphetamines should be energetically pursued.
Insights
Methamphetamine-associated cardiomyopathy (MAC) is a growing global health concern. Effective management requires methamphetamine abstinence, optimal heart failure therapy, and multidisciplinary support for better patient outcomes.
Area of Science:
- Cardiology
- Toxicology
- Public Health
Background:
- Methamphetamine use is increasing globally, leading to a rise in methamphetamine-associated cardiomyopathy (MAC).
- MAC presents with high rates of sudden cardiac arrest, delayed diagnosis, and poor prognosis.
- Patients with MAC are often younger and have multisystem disease compared to other cardiomyopathy types.
Purpose of the Study:
- To review the medical management of methamphetamine-associated cardiomyopathy.
- To identify challenges in treating MAC patients, particularly those related to methamphetamine use.
- To emphasize optimal treatment strategies for improved patient outcomes.
Main Methods:
- This is a review article discussing the medical management of MAC.
- It synthesizes current knowledge on MAC diagnosis, treatment, and challenges.
- Focuses on the specific needs of methamphetamine users.
Main Results:
- MAC management requires addressing unique challenges in methamphetamine users, including behavioral and psychosocial factors.
- Individualized treatment plans are crucial, prioritizing methamphetamine abstinence.
- Optimal heart failure therapy and multidisciplinary support are essential for recovery.
Conclusions:
- Methamphetamine-associated cardiomyopathy is potentially reversible.
- Abstinence from methamphetamine is the cornerstone of effective MAC treatment.
- Guideline-directed heart failure therapy, coupled with robust patient support, is vital for optimal outcomes.
More Related Videos
09:16A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
05:04In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
Published on: February 22, 2022
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Myocarditis III: Medical Management
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Myocarditis IV: Nursing Management
Cardiomyopathy IV: Restrictive Cardiomyopathy